Answers are grounded in this paper and cite their sources.
In vitro study demonstrates that ACE2 co-expression with TMPRSS2 drives SARS-CoV-2 pseudovirus susceptibility in lung cancer cells, highlighting key targets to reduce infection severity.
Background Non-small cell lung cancer (NSCLC) patients often experience worse complications from coronavirus disease 2019 (COVID-19). The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection starts as the viral spike (S) protein attaches to angiotensin-converting enzyme 2 (ACE2), requiring transmembrane protease serine 2 (TMPRSS2) as a co-receptor. Additionally, glucose-regulated protein 78 (GRP78) may serve as an alternative receptor in certain conditions. However, studies on the expression of ACE2, TMPRSS2, and GRP78 in NSCLC and their association with SARS-CoV-2 susceptibility remain limited. This study investigates whether NSCLC receptor expression increases SARS-CoV-2 infection risk. Methods This study evaluated protein and gene expression of ACE2, TMPRSS2, and GRP78 in NSCLC cell lines (Calu-3, A549, H460) versus normal lung fibroblasts (MRC5) using flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and assessed whether their expression increases SARS-CoV-2 infection risk via SARS-CoV-2 pseudovirus transduction. Results Results showed higher ACE2 and TMPRSS2 expression and greater susceptibility to SARS-CoV-2 pseudovirus in Calu-3, whereas A549 and H460 showed higher TMPRSS2 protein levels but unchanged ACE2 expression and viral susceptibility. No significant association was also observed between GRP78 levels and SARS-CoV-2 pseudovirus infection severity in NSCLC cells. Conclusion These findings suggest that ACE2 and TMPRSS2 levels are positively correlated with SARS-CoV-2 pseudovirus infectivity. Moreover, elevated TMPRSS2 expression alone is insufficient to enhance susceptibility unless accompanied by increased ACE2 expression. This study highlights potential therapeutic targets for mitigating SARS-CoV-2 infection risk in NSCLC patients by modulating receptor expression.
No takes yet. Share an insight, caveat, or question.
Talebiashtiany et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: